TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04280510

Intervention type: GENETIC
Intervention: Blood sample collection; gastrointestinal biopsy
Description: Targeted Next generation sequencing and whole exome sequencing Phenotyping of intestinal lymphocytes, single cell analyses, cytokines dosage...

Intervention type: GENETIC
Intervention: Blood sample collection; gastrointestinal biopsy
Description: Targeted Next generation sequencing and whole exome sequencing Phenotyping of intestinal lymphocytes, single cell analyses, cytokines dosage...

Intervention type: GENETIC
Intervention: Blood sample collection; gastrointestinal biopsy
Description: Targeted Next generation sequencing and whole exome sequencing Phenotyping of intestinal lymphocytes, single cell analyses, cytokines dosage...

Intervention type: GENETIC
Intervention: Blood sample collection; gastrointestinal biopsy
Description: Targeted Next generation sequencing and whole exome sequencing Phenotyping of intestinal lymphocytes, single cell analyses, cytokines dosage...

Intervention type: GENETIC
Intervention: Blood sample collection; gastrointestinal biopsy
Description: Targeted Next generation sequencing and whole exome sequencing Phenotyping of intestinal lymphocytes, single cell analyses, cytokines dosage...
Study: NCT04214314

Intervention type: BEHAVIORAL
Intervention: NeuronUp APT attentional program
Description: NeuronUp APT attentional program consists of 4 types of attention with 20 activities each and 5 different levels of difficulty per activity. These 20 activities will be divided into two blocks (block A or block B) of 10 activities each and then, randomly, participants will be administered one block or another. The administration of the entire program is approximately one month and a half or 2 months per patient, with sessions of one hour, 3 times per week.
Study: NCT03099668

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Visit to a multidisciplinary clinic
Description: Visit to a multidisciplinary clinic
Study: NCT01989767

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: control Rehabilitation as usual
Description: Rehabilitation as usual

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: education
Description: Education as add on to to rehabilitation as usual
Study: NCT02818088

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: n-Back (Cognitive Training)
Study: NCT00597467

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VISA (comfilcon A) Silicone Hydrogel Soft contact lens
Description: Test device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acuvue 2 Soft Contact Lens
Description: Control device
Study: NCT00398970

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endobronchial ultrasound miniprobe
Description: Endobronchial ultrasound miniprobe is used to identify solid mass in lung parenchyma.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Endobronchial ultrasound miniprobe
Description: Endobronchial ultrasound miniprobe is used to identify solid mass in lung parenchyma.
Study: NCT02901041

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zonisamide
Description: ZONEGRAN® (zonisamide) is an antiseizure drug chemically classified as a sulfonamide and unrelated to other antiseizure agents. A dose of 400 mg daily will be used as the target maintenance dose in this study but dosing will be modified if needed to adjust for subject tolerance of drug dosing.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Take Control
Description: Take Control is a seven module computer-based intervention which presents evidence-based alcohol education that includes motivational interviewing and cognitive-behavioral skills building. This program is derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA's) self-help approach, Rethinking Drinking.~Starting on March 23, 2020, participants will participate in a simplified Take Control treatment at home due to the COVID-19 pandemic

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Take Control
Description: Take Control is a seven module computer-based intervention which presents evidence-based alcohol education that includes motivational interviewing and cognitive-behavioral skills building. This program is derived from the National Institute on Alcohol Abuse and Alcoholism's (NIAAA's) self-help approach, Rethinking Drinking.~Starting on March 23, 2020, participants will participate in a simplified Take Control treatment at home due to the COVID-19 pandemic

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo (for Zonisamide)
Description: Sugar pills manufactured to mimic Zonisamide capsules.
Study: NCT00747630

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: An educational video about Fetal Alcohol Syndrome
Description: A 20 minute video about FAS
Study: NCT00892177

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Description: Given intravenously

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: bevacizumab
Description: Given intravenously

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dasatinib
Description: Given orally

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: placebo
Description: Given orally
Study: NCT01758263

Intervention type: DRUG
Intervention: Metoprolol
Description: Metoprolol, oral administration

Intervention type: DRUG
Intervention: Nebivolol
Description: Nebivolol, oral administration
Study: NCT04011254

Intervention type: PROCEDURE
Intervention: haemodialysis
Description: Routine haemodialysis session

Intervention type: PROCEDURE
Intervention: haemodialysis
Description: Routine haemodialysis session
Study: NCT00465244

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam 1 g IV + Lorazepam 2 mg IV
Description: Levetiracetam 1 g IV + Lorazepam 2 mg IV

Intervention type: DRUG
Group type: OTHER
Intervention: Placebo + Lorazepam 3 mg IV
Description: Placebo + Lorazepam 3 mg IV
Study: NCT03085108

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No Intervention
Description: No Intervention
Study: NCT02281279

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Given IV

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lenalidomide
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: romidepsin
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study: NCT01074671

Intervention type: DEVICE
Group type: OTHER
Intervention: CG Future Annuloplasty Ring/Band
Description: A CG Future Annuloplasty Ring or Band will be implanted, following standard care
Study: NCT00701870

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ezatiostat hydrochloride (Telintra®)
Description: 4500 mg orally per day in two divided doses
Study: NCT00913354

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Acupuncture (Carbo®)
Description: The acupuncture points were chosen according to traditional Chinese medicine and included DU20, M29, KS6, Mp8, and Le3 before embryo transfer and DU20, Co4, Mp10, M36, and Mp6 after embryo transfer.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo acupuncture (Strietberger®)
Description: The acupuncture points were the same as in the true acupuncture group, namely DU20, M29, KS6, Mp8, and Le3 before embryo transfer and DU20, Co4, Mp10, M36, and Mp6 after embryo transfer.~Sham acupuncture needles used were the validated Strietberger® placebo-needle from the company, Asia Med. The needle is not fixed inside the copper handle and its tip is blunt. When the needle touches the skin it moves inside the handle and appears to be shortened. A pricking sensation is felt by the patient, simulating the puncturing of the skin. Developed by dr. Konrad Streitberger.
Study: NCT02809573

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chidamide
Description: In the lead-in period, patients take a single dose of Chidamide tablet on the first day and then off for 3 days before the first cycle begins. In the subsequent treatment cycles, Chidamide tablets are given orally on Day 1,4,8 and 11 of each cycle.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: On Day 1, cyclophosphamide is given in a 20-minute intravenous (IV) infusion at 750 mg/m\^2 in 5 minutes after chidamide administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: adriacin
Description: On Day 1, Adriacin is given in a 20-minute IV infusion at 50 mg/m\^2 soon after cyclophosphamide administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: vincristine
Description: On Day 1, vincristine is given in IV infusion at 1.4 mg/m\^2 after adriacin administration.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prednisone
Description: On Day 1 to 5, prednisone is given orally at 100 mg once a day
Study: NCT00795951

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: T.R.U.E. Test
Description: 48 hour application of 28 allergens and negative control
Study: NCT04322422

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Inhaled corticosteriod/long-acting beta-agonist plus Montelukast
Description: Inhaled corticosteriod/long-acting beta-agonist are regular inhaled drugs for classic asthma; Montelukast is benefitial for allergic disease

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Inhaled corticosteriod/long-acting beta-agonist only
Description: Inhaled corticosteriod/long-acting beta-agonist are regular inhaled drugs for classic asthma
Study: NCT01842685

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bladder Thermal Distention
Description: Bladder Thermal Distention is an approved procedure in Europe from 2006. The treatment is hydrodistention of the bladder with a warm saline (up to 45C). The procedure lasts 1 hour. The saline is infused constantly through a 3 ways specific catheter (Unithermia 18F) by the PelvixTT system.
Study: NCT01625572

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Transversus abdominis plane blockade
Description: Bilateral one time injection of local anaesthetic in the space between the transversus abdominis muscle and obliquus internus muscle preoperatively. Follow up for three days.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Morphine-patient-controlled-analgesia-device
Description: Morphine-patient-controlled-analgesia-device for three days: 1mg/ml, Dosage 2mg bolus injection on demand every 10 minutes possible.
Study: NCT00065325

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: intramuscular injection

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Exemestane
Description: oral capsule
Study: NCT00984425

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib and Sorafenib
Description: Comparison of different dosages of two drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib and Sorafenib
Description: Comparison of different dosages of two drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib and Sorafenib
Description: Comparison of different dosages of two drug

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lapatinib and Sorafenib
Description: Comparison of different dosages of two drug
Study: NCT04370977

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Coartem™ (Artemether-lumefantrine combination)
Description: AL (Coartem™) was administered twice daily for three days (six doses in total) with dosage determined according to body weight: one tablet (20mg artemether and 120mg lumefantrine) for children 5 to \<15kg, two tablets per dose for those 15 to \<25kg, and three tablets per dose for those 25 to \<35kg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Winthrop™ (Amodiaquine-artesunate combination)
Description: AQ-AS (Coarsucam™) was administered once daily according to body weight: one 25mg artesunate and 67.5mg amodiaquine tablet in children \<9kg, one 50mg artesunate and 135mg amodiaquine tablet in children 9-17.9kg; and one 100mg artesunate and 270mg amodiaquine tablet in children \>18-35kg.
Study: NCT01888835

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mirtazapine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00764933

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Structured information
Description: Participants will receive structured information about their ICU-stay and course of therapy and care. They get information about procedures, sensory impressions and coping strategies. The intervention will last about 10 to 15 minutes depending on the state of the participant.

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Unspecific conversation
Description: Participants will receive a short conversation with the study personnel. This conversation will last about 10 to 15 minutes. No specific informations will be given about procedures, sensory impressions or coping strategies. Control intervention is designed to control for personal attention and care.
Study: NCT04294069

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin 500 mg
Description: 500mg azithromycin PO for seven days starting on admission

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Azithromycin Oral Product
Description: 1000mg azithromycin PO once at admission
Study: NCT03942406

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device
Description: Live attenuated pertussis vaccine administered via the VaxINator(TM) atomization device

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device
Description: Live attenuated pertussis vaccine administered via the VaxINator(TM) atomization device

Intervention type: COMBINATION_PRODUCT
Group type: EXPERIMENTAL
Intervention: BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device
Description: Live attenuated pertussis vaccine administered via the VaxINator(TM) atomization device

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: BPZE1 pertussis vaccine and VaxINator(TM) Atomization Device
Description: Live attenuated pertussis vaccine administered via the VaxINator(TM) atomization device
Study: NCT03445988

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Cognitive Behavioral Therapy
Description: A trained psychologist delivers pain-CBT to individual patients or groups of patients with chronic pain. Group treatment is delivered across 8 weekly sessions that last for 2 hours each. Pain-CBT incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session. Pain-CBT is effective for reducing pain intensity, pain catastrophizing, depression and social impacts.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Chronic Pain Self Management Program
Description: The CPSMP is similar to pain-CBT in format and content but is peer-led, and is effective across pain conditions (e.g., back pain, arthritis) for improving pain and pain self-efficacy. The CPSMP consists of six weekly 2-hour group sessions in which two peer co-leaders provide patient education about pain, effective self-management, pain impacts, and other symptoms from a highly structured manual. Similar to pain-CBT, CPSMP incorporates interactive discussion, practice of relaxation training, action planning, and home exercises into each session

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Usual Care
Description: Participants allocated to 'Taper Only' will engage in a physician-guided, patient-centered opioid tapering program without additional behavioral intervention.
Study: NCT00483314

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-acetylcysteine
Description: 2 g p.o. BID x 60 days
Study: NCT01138007

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 323U66 SR 150 mg tablet
Description: 323U66 SR 150 mg tablet is orally administered once in the morning and/or once in the evening during the teatment phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 323U66 SR 150 mg tablet
Description: 323U66 SR 150 mg tablet is orally administered once in the morning and/or once in the evening during the teatment phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 323U66 SR 150 mg placebo tablet
Description: 323U66 SR 150 mg placebo tablet is orally administered once in the evening and/or once in the morning during the teatment phase.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 323U66 SR 150 mg placebo tablet
Description: 323U66 SR 150 mg placebo tablet is orally administered once in the evening and/or once in the morning during the teatment phase.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: 323U66 SR 150 mg placebo tablet
Description: 323U66 SR 150 mg placebo tablet is orally administered once in the evening and/or once in the morning during the teatment phase.
Study: NCT02682472

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: SettleIN - Adjustment to care programme
Description: A programme for care home staff to support new residents with dementia quickly and successfully adjust to life in a care home
Study: NCT01245075

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep brain stimulation
Description: Deep brain stimulation on

Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Placebo
Description: deep brain stimulation off
Study: NCT04930224

Intervention type: DIAGNOSTIC_TEST
Intervention: The effect of GPER-1 on the formation of diabetic retinopathy
Description: Demonstrating the neuroprotective effect of GPER-1 in the formation of diabetic retinopathy and being a guide for new treatment models

Intervention type: DIAGNOSTIC_TEST
Intervention: The effect of GPER-1 on the formation of diabetic retinopathy
Description: Demonstrating the neuroprotective effect of GPER-1 in the formation of diabetic retinopathy and being a guide for new treatment models

Intervention type: DIAGNOSTIC_TEST
Intervention: The effect of GPER-1 on the formation of diabetic retinopathy
Description: Demonstrating the neuroprotective effect of GPER-1 in the formation of diabetic retinopathy and being a guide for new treatment models
Study: NCT03548987

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Semaglutide
Description: Subcutaneous (under the skin) injection of semaglutide once-weekly.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Semaglutide
Description: Subcutaneous (under the skin) injection of semaglutide once-weekly.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Subcutaneous (under the skin) injection of semaglutide placebo once-weekly.
Study: NCT02741583

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: altitude rehabilitation program
Description: altitude exposure

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: rehabilitation program
Description: Rehabilitation at low altitude
Study: NCT02838147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle sensors.
Description: Patients with normal OGTT (4 normal values) - will be allocated to 2-week period to FreeStyle sensors.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle sensors.
Description: Patients with normal OGTT (4 normal values) - will be allocated to 2-week period to FreeStyle sensors.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FreeStyle sensors.
Description: Patients with normal OGTT (4 normal values) - will be allocated to 2-week period to FreeStyle sensors.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucometer
Description: Patients with pathological OGTT - 1 abnormal value Patients with pathological OGTT - 2 abnormal value

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Glucometer
Description: Patients with pathological OGTT - 1 abnormal value Patients with pathological OGTT - 2 abnormal value
Study: NCT03292861

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Thymoglobulin
Description: Approximately half of the patients will be randomized to receive a total of 5 doses of Thymoglobulin during the study. The first dose of Thymoglobulin will be administered at 1.5 mg/kg via intravenous infusion over 8 hours immediately upon arrival to the ICU post-operation (day 1). Subsequent doses of 1.5 mg/kg will be administered on days 2, 3, 4, and 5 via IV infusion over 4-8 hours.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Mycophenolate Mofetil
Description: 3.0 grams divided bid begun post-transplant, either IV or po as tolerated by patient. Initial dose must be given within 24 hours post-transplant. Dosing will be titrated based on recipient's body size and any adverse side effects

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tacrolimus
Description: Doses of 1-4 mg bid either IV or po will be prescribed to achieve a target trough level of 10-15 ng/mL before post-operative day number 5. Target trough levels are 10-15 ng/mL for post-operative days #1-30, 8-12ng/mL days#31-60 and 5-10 ng/mL thereafter.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sirolimus
Description: Maintenance doses of sirolimus at 12 months post-transplantation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Corticosteroids
Description: 125 mg IV methylprednisolone immediately post-operatively x 3 doses q12hrs, then switching to oral prednisone at 1.0 mg/kg/day po divided into bid doses that are rounded off to the next higher 5 mg increment. For example, a 76 kg person would should be dosed at 38 mg po bid, which rounded off to the next 5 mg increment would be 40 mg po bid. (Equivalent dosing via an alternative route may be used if pos not tolerated or contraindicated). Prednisone will be tapered by 10 mg qd until the dose of 10 mg po bid is reached.
Study: NCT00377247

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: autologous monocyte-derived dendritic cells (DC) transfected with DNA
Description: The patients will receive 1 x 107 DC/vaccine delivered intranodally or perinodally to lymph nodes (LN) distant from the head and neck area (e.g., to inguinal LN)
Study: NCT01774110

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Early standardized task training
Description: Early standardized task training is a treatment approach using treadmill training applied very early after stroke onset.
Study: NCT00640016

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo matched to CAT-354 intravenous infusion over 60 minutes on Day 0, 28 and 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAT-354 1 mg/kg
Description: CAT-354 1 milligram/kilogram (mg/kg) of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CAT-354 5 mg/kg
Description: CAT-354 5 mg/kg of body weight intravenous infusion over 60 minutes on Day 0, 28 and 56.